ストックスクリーナーアプリを入手
84.87
1.39%
-1.20
前日終値:
$86.07
開ける：
$86.16
24時間の取引高:
1.76M
Relative Volume:
0.70
時価総額：
$11.52B
収益：
$105.82M
当期純損益:
$-829.61M
株価収益率:
-12.40
EPS:
-6.8429
ネットキャッシュフロー:
$-548.92M
1週間 パフォーマンス:
-1.87%
1か月 パフォーマンス:
+26.54%
6か月 パフォーマンス:
+35.77%
1年 パフォーマンス:
+131.95%
1日の値動き範囲:
$83.59
$86.45
1週間の範囲:
$82.20
$87.93
52週間の値動き範囲:
$32.89
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
84.87 | 11.52B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Wells Fargo | Overweight |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced? - Yahoo Finance
How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story - Yahoo Finance
Price to sales forward of Cytokinetics, Incorporated – NASDAQ:CYTK - TradingView
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside - TradingView
FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A - Stock Titan
CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market - Stock Titan
CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale - Stock Titan
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo By Investing.com - Investing.com Nigeria
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo - Investing.com
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $117 - Moomoo
CYTK Maintained by RBC Capital -- Price Target Lowered to $117 - GuruFocus
RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating - marketscreener.com
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 - The Manila Times
Cytokinetics lands three ESC 2026 presentations on heart drug data - Stock Titan
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of ... - Caledonian Record
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
CYTKCytokinetics Inc Latest SEC Filings - Finviz
Cytokinetics CEO Robert Blum sells $636,900 in stock - Investing.com UK
Insider Sell Alert: EVP, Chief Financial Officer Sung Lee Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Cytokinetics EVP Andrew Callos sells $1.29 million in shares - Investing.com UK
Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.29 million in shares By Investing.com - Investing.com South Africa
Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale - Stock Titan
Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80 - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79 - Stock Titan
Form 144 CYTOKINETICS For: 1 July By Investing.com - Investing.com UK
CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK) - Stock Titan
Cytokinetics Inc stock hits 52-week high at $88.00 - Investing.com
Cytokinetics Inc stock hits 52-week high at $88.00 By Investing.com - Investing.com India
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK) - The Globe and Mail
Cytokinetics CFO Lee Sung sells $3.18m in company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $3.18m in company stock - Investing.com
Form 144 CYTOKINETICS For: 29 June By Investing.com - Investing.com South Africa
Form 4 Cytokinetics Inc For: 29 June By Investing.com - Investing.com South Africa
Cytokinetics(CYTK.US) Officer Sells US$3.19 Million in Common Stock - Moomoo
Cytokinetics (CYTK) CFO sells 38,730 shares at $82.30 after exercising options - Stock Titan
Cytokinetics CFO Lee Sung sells $266,390 of company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $266,390 of company stock - Investing.com
Cytokinetics (NASDAQ: CYTK) CFO trades shares after option exercises - Stock Titan
Option exercise and 10b5-1 sales reported by CYTK (NASDAQ: CYTK) - Stock Titan
CYTK Upgraded by UBS -- Price Target Raised to $115 - GuruFocus
Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now? - Insider Monkey
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):